Related Experiment Video

Updated: Mar 6, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML

Andrew M Brunner, Wendy Stock

    Oncology (Williston Park, N.Y.)
    |March 17, 2017
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    871
    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    1.0K

    Related Experiment Videos

    Last Updated: Mar 6, 2026

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 18, 2013

    18.7K
    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    871
    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    1.0K

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    6.3K
    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.3K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.8K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.8K

    Articles linked to this work by shared authors, journal, and citation graph.

    Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

    The New England journal of medicine·2026

    Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

    American journal of hematology·2026

    OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

    Blood·2026

    Adolescents and Young Adults With Acute Lymphoblastic Leukemia: Qualitative Barriers and Facilitators to Guideline-Concordant Care.

    Cancer control : journal of the Moffitt Cancer Center·2026

    Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

    American journal of hematology·2026

    A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

    Blood advances·2026

    Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer.

    Oncology (Williston Park, N.Y.)·2026

    Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City.

    Oncology (Williston Park, N.Y.)·2026

    Access to Care and Drug Prices: Recent Department of Health and Human Services Guidance.

    Oncology (Williston Park, N.Y.)·2026

    Clinical Outcomes of Acute Pancreatitis in Patients With Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026

    Primary Malignant Melanoma of the Colon: A Rare and Challenging Diagnosis.

    Oncology (Williston Park, N.Y.)·2026

    Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026

    Postoperative radiotherapy or chemoradiotherapy versus surgery only in non-metastatic head and neck adenoid cystic carcinoma: a retrospective analysis.

    Translational cancer research·2026

    Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in stage IIIB-IV squamous non-small cell lung cancer: a systematic review and meta-analysis of phase 3 randomized controlled trials.

    Translational cancer research·2026

    Erratum: Nomogram for predicting cancer-specific mortality risk in endometrial cancer after postoperative radiotherapy.

    Translational cancer research·2026

    Neoadjuvant anthracycline-containing vs. anthracycline-free chemotherapy with dual HER2 blockade in HER2-Positive breast cancer: a Systematic Review and meta-analysis.

    Open medicine (Warsaw, Poland)·2026

    The expert consensus document on minimally invasive upper lobectomy for lung cancer in China.

    Journal of thoracic disease·2026

    Belzutifan-Associated Reversible Heart Failure With Preserved Ejection Fraction in Metastatic Renal Cell Carcinoma.

    IJU case reports·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us